[March 06, 2014] |
 |
Ensysce Biosciences Inc. Receives Notice of Allowance for U.S. Patent for Delivery of siRNA
HOUSTON --(Business Wire)--
Ensysce Biosciences Inc. announced today that the U.S. Patent Office has
issued a Notice of Allowance for U.S. Patent Application No. 13/175,314:
SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED
THERETO. The application has claims covering methods of delivering
single walled carbon nanotube (SWCNT) complexes with siRNA for
therapeutic applications.
The patent will extend the intellectual property coverage of Ensysce and
add to the extensive package of patents for the use of SWCNT for
therapeutic applications licensed to Ensysce worldwide.
Carbon nanotubes provide a means to deliver large biologically active
agents through natural barriers within the body and readily into cells
in a number of tissues that have previously een difficult to deliver
to. "Our demonstration of SWCNT delivery of siRNA into tissues and
specifically tumors in animal models has allowed us to begin moving this
delivery platform into clinical development," said Dr. Lynn Kirkpatrick,
CEO of Ensysce. "We have optimized the formulation of our complexes and
have begun studies to support our IND that will lead to a clinical trial
in the next 12 to 15 months. This Notice of Allowance confirms the
novelty of our approach and significantly enhances the scope of our
protection."
"siRNA has issues with adequate cellular delivery, yet is one of the
most intriguing and promising approaches to cancer therapy today," said
Dr. Garth Powis, Director of the NCI Designated Sanford Burnham Cancer
Center and member of the Ensysce Scientific Advisory Board. "Ensysce's
success in using carbon nanotubes to deliver these macromolecules
providing biological activity in tumors is a major accomplishment."
About Ensysce Biosciences:
Ensysce is located in the Biotechnology Commercialization Center in the
Texas Medical Center and is focused on the use of carbon nanotubes for
therapeutics in the area of cancer treatment. The company has an
extensive carbon nanotube-related, worldwide intellectual property
portfolio, including IP developed at Rice University by the late Nobel (News - Alert)
Prize winner Dr. Richard Smalley as well as from the University of
Florida and Trinity College in Dublin.

[ Back To TMCnet.com's Homepage ]
|